<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Most authors agree upon the causal association between <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> [<z:e sem="disease" ids="C0024138,C0024141,C0024131,C0409974" disease_type="Disease or Syndrome" abbrv="">lupus</z:e> <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> (LAC) and/or anticardiolipin antibodies] and adverse pregnancy outcome </plain></SENT>
<SENT sid="1" pm="."><plain><z:mp ids='MP_0006372'>Placental insufficiency</z:mp>, caused by <z:mp ids='MP_0005048'>thrombosis</z:mp>, infarction and maldevelopment, is thought to be the main cause of fetal loss in patients with LAC </plain></SENT>
<SENT sid="2" pm="."><plain>Therapy given thus far to prevent fetal loss can be divided into (1) immunosuppression by <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, <z:chebi fb="2" ids="2948">azathioprine</z:chebi>, or intravenous gamma globulin (IVGG), (2) anti-aggregants to overcome imbalance of <z:chebi fb="0" ids="26995">thromboxane</z:chebi>/prostacycline production in patients with LAC, and (3) <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> to neutralize the possible impairment of clotting inhibitor systems </plain></SENT>
<SENT sid="3" pm="."><plain>Different therapeutic success rates have been reported by various authors who used the same combination of therapy </plain></SENT>
<SENT sid="4" pm="."><plain>We report the results of different therapy regimens in 154 pregnancies in 31 women with LAC </plain></SENT>
<SENT sid="5" pm="."><plain>These patients suffered from SLE with LAC or from APLA syndrome and experienced either <z:e sem="disease" ids="C0000809" disease_type="Disease or Syndrome" abbrv="">recurrent miscarriages</z:e> or thromboembolic phenomena in the past </plain></SENT>
<SENT sid="6" pm="."><plain>With no therapy there were seven (6.8%) live births and 95 (93.2%) failures </plain></SENT>
<SENT sid="7" pm="."><plain>Various combinations of <z:chebi fb="0" ids="50858">corticosteroids</z:chebi>, anti-aggregants and <z:chebi fb="2" ids="50249">anticoagulants</z:chebi> were used for treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Of 52 treated pregnancies, 27 (51.9%) were successful </plain></SENT>
<SENT sid="9" pm="."><plain>Sixteen (69.1%) of 23 pregnancies treated by <z:hpo ids='HP_0000001'>all</z:hpo> three modalities ended in live births </plain></SENT>
<SENT sid="10" pm="."><plain>Four of these successful pregnancies occurred after failure of treatment by <z:chebi fb="0" ids="8382">prednisone</z:chebi> and anti-aggregants only </plain></SENT>
<SENT sid="11" pm="."><plain>In order to minimize <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> caused by the combination of steroids and <z:chebi fb="5" ids="28304">heparin</z:chebi>, we have used <z:chebi fb="8" ids="10033">warfarin</z:chebi> in the second trimester and have lately substituted low molecular weight <z:chebi fb="5" ids="28304">heparin</z:chebi> for <z:chebi fb="5" ids="28304">heparin</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>In the absence of a therapeutic schedule predicated on a large prospective study, therapy during pregnancy in patients having LAC should be individualized according to their obstetric and medical history.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>